Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
New England Journal of Medicine2018Vol. 379(8), pp. 722–730
Citations Over TimeTop 1% of 2018 papers
Hussein A. Tawbi, Peter Forsyth, Alain P. Algazi, Omid Hamid, F. Stephen Hodi, Stergios J. Moschos, Nikhil I. Khushalani, Karl D. Lewis, Christopher D. Lao, Michael A. Postow, Michael B. Atkins, Marc S. Ernstoff, David A. Reardon, Igor Puzanov, Ragini R. Kudchadkar, Reena Thomas, Ahmad A. Tarhini, Anna C. Pavlick, Joel Jiang, Alexandre Avila, Sheena Demelo, Kim Margolin
Abstract
Nivolumab combined with ipilimumab had clinically meaningful intracranial efficacy, concordant with extracranial activity, in patients with melanoma who had untreated brain metastases. (Funded by Bristol-Myers Squibb and the National Cancer Institute; CheckMate 204 ClinicalTrials.gov number, NCT02320058 .).
Related Papers
- → Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma(2019)3,640 cited
- → Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab(2021)13 cited
- → Utility Values Across Lines of Therapy in Immuno-Oncology Treatments: An Example from Advanced Melanoma(2017)
- → Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients(2023)
- → TNFSF9 is associated with favor tumor immune microenvironment in patients with renal cell carcinoma who are treated with the combination therapy of nivolumab and ipilimumab(2024)